CELLDEX THERAPEUTICS INC reports a Return on Equity (ROE) of -62.18%.

What is CLDX's dividend yield?

CELLDEX THERAPEUTICS INC offers a dividend yield of 0.00%.

What is CLDX's Quality Score?

Our AI rates CLDX's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy CLDX?

Our AI Timing Score for CLDX is 89 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does CLDX belong to?

CELLDEX THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

CLDX (NASDAQ) Stock Analysis | CELLDEX THERAPEUTICS INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

CLDX AI Analysis Summary

Our AI summary for CLDX: CELLDEX THERAPEUTICS INC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -62.18%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 89/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

CLDX

CELLDEX THERAPEUTICS INC

US:NASDAQ STOCK Healthcare >> Biotechnology News 97

USD 38.06

-0.43 (-1.10%) Day Change

Watchlist Portfolio Compare Chart

0.00

D/E

-62.2%

ROE

-55.5%

ROA

0.00%

Div Yield

CELLDEX THERAPEUTICS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 38.06 Price -0.43 (-1.10%) Day Change	NEWS SCORE: 97

CLDX, the overall quality is not good ( Quality = 23) but the timing to buy is ...(Sign In to See)...

Loading chart...

23 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	97
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	38.06
PBV / Sector	6.62 / 5.20
Earning Per Share	-3.57

PE / Sector	N/A / 19.97
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	34.10 M GREAT
Average 1W Daily Value	35.08 M GREAT

Timing Factors

71%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

52%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-34,596.22 / 98.71
NPM Average (%) / Sector	-12,183.73 / -1,721.76
NPM Change Average (%) / Sector	180.08 / 5,211.62 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-55.49 / 27.02
ROA Average (%) / Sector	-36.40 / -368.17
ROA Change Average (%) / Sector	27.20 / 5,404.12 GREAT
ROE (%) / Sector	-62.18 / 3.47
ROE Average (%) / Sector	-39.96 / 6.51
ROE Change Average (%) / Sector	29.70 / 2,128.13 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 07:59:38
Symbol	CLDX
Name	CELLDEX THERAPEUTICS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	78.49 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	3,020.77 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: Perryville III Building, Hampton, NJ, United States, 08827

Phone: 908 200 7500

Website: https://www.celldex.com

Employees: 198

Sector: Healthcare >> Biotechnology

Description: Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.